Cellectar Biosciences, Inc.

Quick facts

Phase 2 pipeline

• I-131-CLR1404
• Iopofosine I 131 fractionated dose
• Iopofosine I 131 multiple dose
  Iopofosine I 131 is a radioiodinated phospholipid ether analog that selectively accumulates in cancer cells and delivers targeted radiation therapy.
• Iopofosine I 131 single dose · Oncology
  Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy.
• NOV-205

Phase 1 pipeline

• CLR 125

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cellectar Biosciences, Inc. portfolio CI brief
• Cellectar Biosciences, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies